MiMedx to Present Clinical and Scientific Studies at SAWC Fall Meeting
The conference begins Friday, November 2nd and concludes on Sunday, November 4th. MiMedx will be exhibiting in booth #207 during all booth times throughout the three-day meeting.
MiMedx will also sponsor a Breakfast Symposium entitled, "PURION® Processed Placental Based Allografts – The Use of Bioactive Tissue Matrices in the Treatment of Wounds," on Friday, November 2nd, from 7:30 a.m. to
Michelle Massee , Manager ofBiomedical Research ,MiMedx William Tettelbach , MD, Associate Chief Medical Officer,MiMedx James Stavosky , DPM
In addition, MiMedx is sponsoring two educational presentations. The first event will be held on Friday, November 2nd, at 7:30 p.m. with James Stavosky, DPM, presenting, "PURION® Processed Placental Based Allografts: Effective Tools in the Clinic and the Surgical Suite." The second event will be held on Saturday, November 3rd, at 7:00 p.m., with Matthew Garoufalis, DPM, FASPS, FACFAOM, presenting, "Using PURION® Processed Placental Tissue Products for Wound Healing and in Surgery." In-booth demonstrations will be offered by physicians David Kyle, DPM, and Brandon Hawkins, DPM, in the MiMedx booth #207 during exhibit hours.
The five poster abstracts will report on clinical studies of MiMedx EpiFix and EpiCord and chronicle independent case studies relative to MiMedx allografts. The five abstracts will consist of:
1. Highest Scoring Clinical Research Abstract -
2.
3.
4.
5.
About
MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.
View original content:http://www.prnewswire.com/news-releases/mimedx-to-present-clinical-and-scientific-studies-at-sawc-fall-meeting-300741452.html
SOURCE
Robert P. Borchert, Vice President, Investor Relations, 770-651-9383, rborchert@mimedx.com